Skip to main content
. Author manuscript; available in PMC: 2019 Sep 16.
Published in final edited form as: J Neuroimmune Pharmacol. 2016 Apr 16;11(2):369–377. doi: 10.1007/s11481-016-9670-0

Fig. 6.

Fig. 6

Lesional area in a non-sensitized CCM murine model after B cell depletion. Anti-BR3 antibody treatment of Pdcd10+/− mice did not reduce a) the area of stage 1 pre-lesions, but significantly reduced b) the area of mature stage 2 lesions and c) total area of lesions compared to randomly untreated mice raised contemporaneously, and assessed blindly. Horizontal lines indicate the mean (longer lines) and standard error of the mean (shorter lines)